Here are a few brief analogies for Puma Biotechnology:

• A specialized biotech company focused on developing and commercializing HER2-positive cancer treatments, much like a smaller, more focused Genentech.

• A biopharmaceutical company dedicated to developing targeted cancer therapies, akin to a specialized version of Vertex Pharmaceuticals but for oncology.

```html

• PB272 neratinib (oral): An oral drug candidate for patients with early-stage HER2-overexpressed/amplified breast cancer.
• PB272 (neratinib, oral) in combination with capecitabine: An oral drug combination used to treat adult patients with advanced or metastatic HER2-positive breast cancer.
• PB272 (neratinib, oral) for HER2 mutation-positive solid tumors: An oral drug candidate targeting solid tumors with HER2 mutations.

```

Major Customers of Puma Biotechnology (PBYI)

Puma Biotechnology primarily sells its drug candidates through licensing agreements to other pharmaceutical companies, which then commercialize and distribute the products in specific territories. Based on the provided background, the company's major customers (or commercial partners via sub-licensing agreements) include:

• Pfizer, Inc. (NYSE: PFE)
• Specialised Therapeutics Asia Pte Ltd.
• CANbridge BIOMED Limited
• Pint Pharma International SA
• Knight Therapeutics, Inc. (TSX: KHT)
• Pierre Fabre Medicament SAS
• Bixink Therapeutics Co., Ltd.

null

Alan H. Auerbach, Chief Executive Officer, President and Chairman of the Board Mr. Auerbach has served as Puma Biotechnology's Chairman of the Board, Chief Executive Officer, and President since the company's inception. Prior to founding Puma, he was the Founder, Chief Executive Officer, President, and a Member of the Board of Directors of Cougar Biotechnology, Inc., from its inception in 2003 until its acquisition by Johnson & Johnson in July 2009 for approximately $1 billion. Following the acquisition, he served as Co-Chairman of the Integration Steering Committee at Cougar (as part of Johnson & Johnson) focusing on the development and global commercialization of abiraterone acetate. Before founding Cougar, Mr. Auerbach was Vice President, Senior Research Analyst at Wells Fargo Securities, covering small- and middle-capitalization biotechnology companies, and previously a Vice President, Research Analyst at Seidler Companies, Inc. Maximo F. Nougues, Chief Financial Officer Mr. Nougues joined Puma Biotechnology as Chief Financial Officer in November 2018. Prior to Puma, he worked for Getinge AB, a global medical device company, from January 2008 to October 2018, holding several leadership positions including regional chief financial officer for North America and the Americas. Before Getinge, Mr. Nougues held finance roles in Boston Scientific's cardiac surgery division (which Getinge acquired in 2008) and at The Clorox Company from 1998 to 2007. Douglas Hunt, Chief Regulatory Affairs, Medical Affairs, and Pharmacovigilance Officer Mr. Hunt joined Puma Biotechnology in January 2018 as Senior Vice President of Regulatory Affairs, Medical Writing and Project Management. He has over 25 years of regulatory affairs experience, including serving as Vice President Regulatory Affairs and Quality Assurance at ArmaGen Inc., and Vice President Global Regulatory Affairs (Bioscience) at Baxter International. Earlier in his career, he held various roles at Amgen, including Executive Director, Therapeutic Area Head (Oncology and Bone/Oncology) for Global Regulatory Affairs and Safety. Heather J. Blaber, Senior Vice President, Marketing Ms. Blaber joined Puma Biotechnology as Vice President of Marketing in June 2021 and currently serves as Senior Vice President, Marketing. She brings over 25 years of strategic marketing and sales leadership experience within the biopharmaceutical industry. Roger L. Storms, Senior Vice President of Sales Mr. Storms joined Puma Biotechnology in December 2024, bringing more than 20 years of commercial leadership experience in the biopharmaceutical industry. Before joining Puma, he spent 11 years at Amgen Biotechnology, where he held roles of increasing responsibility, most recently as Eastern U.S. Director of Sales, leading commercial efforts that generated over $3 billion in annual revenue.

Puma Biotechnology, Inc. (PBYI) faces several key risks inherent to its position as a biopharmaceutical company with a primary commercial product. Here are the key risks to Puma Biotechnology:

Heavy Reliance on a Single Commercial Product

Puma Biotechnology's business is predominantly dependent on the success and continued market performance of its single commercial product, NERLYNX (neratinib). Product revenue, which consists entirely of NERLYNX sales, contributed about 95.2% of the total revenue in Q3 2025. While the company is also developing alisertib, the core business's viability is tied directly to neratinib. Any significant challenges to neratinib, such as new competitive drugs, safety concerns leading to market withdrawal, or issues with market adoption, could severely impact the company's financial stability and future prospects.

Intense Competition in the Oncology Market

Puma Biotechnology operates in the highly competitive oncology market, particularly in HER2-positive breast cancer. The efficacy and market share of NERLYNX can be threatened by existing therapies and the continuous emergence of new, potentially more effective, safer, or cheaper treatments from competitors. For example, new novel agents in the adjuvant setting have been noted to lessen the need for extended adjuvant therapy, which is one of NERLYNX's indications. The introduction of other antibody-drug conjugates or other targeted therapies could intensify competitive pressure.

Patent Expiration and Generic Competition

Like all pharmaceutical companies, Puma Biotechnology faces the risk of patent expiration for its key drug, NERLYNX. The primary patent for the composition of matter claims for NERLYNX was extended to expire on December 29, 2030, following a Patent Term Extension Certificate issued by the USPTO. Other patents protecting the drug have various expiration dates, with some expiring as early as October 2025, and a key patent (U.S. Patent No. 8,518,446) set to expire on November 20, 2030. Generic entry for neratinib maleate, the active ingredient in NERLYNX, could occur as early as December 29, 2030, which may change due to patent challenges or generic licensing. There has already been patent litigation involving NERLYNX patents, indicating interest in generic launches. The loss of patent exclusivity will expose NERLYNX to generic competition, which typically leads to a significant decline in revenue and market share.

null

Puma Biotechnology's main product, neratinib (PB272), addresses the following markets:

• Early-stage HER2-overexpressed/amplified breast cancer: The global neratinib market, which is primarily indicated for the extended adjuvant treatment of early-stage HER2-positive breast cancer, was valued at approximately USD 1.3 billion in 2023. It is projected to reach USD 3.8 billion by 2032, demonstrating a compound annual growth rate (CAGR) of 12.7% during the forecast period.

• Advanced or metastatic HER2-positive breast cancer (in combination with capecitabine): The market for metastatic HER2-positive breast cancer in the seven major markets (7MM: United States, Germany, France, the United Kingdom, Italy, Spain, and Japan) was estimated at approximately USD 2.6 billion in 2022 and is expected to grow by 2032. More recently, the 7MM market amounted to USD 2,711.6 million in 2024 and is projected to reach USD 3,108.1 million by 2035. Specifically, in 2023, the HER2-positive breast cancer market in the United States was valued at over USD 1,600 million, with projections for continued growth by 2034. The market size for HER2-positive breast cancer in EU4 and the UK (Germany, France, Italy, Spain, and the United Kingdom) in 2023 exceeded USD 800 million, with expectations of an increase during the period of 2020–2034.

• HER2 mutation-positive solid tumors: Information regarding a specific addressable market size for neratinib for HER2 mutation-positive solid tumors (as a broad category beyond breast cancer) is not available in the provided search results.

Puma Biotechnology (PBYI) anticipates several key drivers for future revenue growth over the next 2-3 years, primarily stemming from its flagship product, Nerlynx (neratinib), and its developing pipeline.

1. Continued Growth in Nerlynx Net Product Sales: Puma Biotechnology expects stable to increasing net product revenue from Nerlynx. In the fourth quarter of 2025, product revenue from Nerlynx increased by nearly 10% year-over-year. For the full year 2026, the company projects net product revenues for Nerlynx to be between $194 million and $198 million. Efforts to manage Nerlynx's side effects, such as implementing a dose escalation strategy where 75% of new patients start on a reduced dose, are expected to improve patient retention and adherence, further supporting sales.

2. Expansion of Royalty Revenues from International Partnerships: Royalty revenues from ex-U.S. partners, particularly from shipments to China, are a significant growth driver. These revenues experienced a substantial increase to $15.6 million in Q4 2025, up from $2.6 million in Q3 2025. Puma forecasts royalty revenues for 2026 to range from $20 million to $23 million, indicating continued growth from its global collaborations.

3. Advancement and Potential Commercialization of Alisertib: The progression of Puma Biotechnology's pipeline asset, alisertib, represents a potential new revenue stream. The company in-licensed alisertib for the treatment of hormone receptor-positive breast cancer and small-cell lung cancer (SCLC). Enrollment in the Phase II trials for alisertib has surpassed expectations, with 150 patients enrolled by February 2026, and interim data is anticipated in the second quarter of 2026. A successful outcome from these trials and subsequent regulatory approvals could lead to the launch of a new product, diversifying and enhancing Puma's revenue.

4. Strategic International Market Penetration for Nerlynx: Beyond existing royalty agreements, Puma Biotechnology is focused on increasing the market penetration of Nerlynx through strategic partnerships for distribution in international markets. The company has established collaborations for Nerlynx distribution outside the U.S., targeting a significant patient population globally. This ongoing expansion into new territories through these partnerships is expected to contribute to overall revenue growth.

Share Issuance

• The number of outstanding shares for Puma Biotechnology consistently increased from approximately 40.99 million at the end of 2021 to 50.33 million at the end of 2025.
• This growth reflects the issuance of approximately 9.34 million new shares over the five-year period from 2021 to 2025.
• The approximate dollar value of shares issued annually, based on the increase in outstanding shares and average yearly stock prices, ranged from approximately $4.95 million (2024-2025) to $13.78 million (2021-2022).

Capital Expenditures

• Puma Biotechnology reported purchases of property, plant and equipment totaling $36,000 in the fourth quarter of 2025.